Triflupromazine

Triflupromazine: Overview

Triflupromazine is a phenothiazine derivative that acts as a central nervous system depressant and antiemetic agent. It is primarily utilized in medical practice to manage acute or severe nausea and vomiting, as well as to control psychotic symptoms.

What Is Triflupromazine & How Does It Work?

Triflupromazine functions primarily as a potent central dopamine D2 receptor antagonist. In the brain stem, it blocks D2 neurotransmitter receptors within the chemoreceptor trigger zone and the vomiting center, effectively halting signals that trigger nausea and emesis. It also blocks dopamine signals along the vagus nerve in the gastrointestinal tract to calm gastrointestinal motility distress. Additionally, Triflupromazine binds to muscarinic acetylcholine receptors (M1 and M2) and serotonin 5-HT2B receptors, which contributes to its sedative and anti-anxiety properties.

Is Triflupromazine FDA Approved?

Triflupromazine received original approval from the United States Food and Drug Administration in October 1957 under the brand name Vesprin, though systemic formulations were later discontinued in the US market. In Gastroenterology and acute clinical settings, medical teams historically utilized Triflupromazine to control severe, intractable nausea and vomiting across complex patient cases.

What Is Triflupromazine Used For?

• Control and management of severe nausea and vomiting induced by surgery or systemic illness.
• Palliative symptom management of acute agitated behavior and psychoses.
• Reducing gastrointestinal upset and autonomic hyperactivity in specialized inpatient care.

Before Taking Triflupromazine: Contraindications & Precautions

Patients must undergo a thorough medical evaluation before receiving Triflupromazine due to its significant central nervous system and cardiovascular effects. Phenothiazine compounds carry specific risks in vulnerable patient populations.

Who Should Not Take Triflupromazine?

Triflupromazine is strictly contraindicated in patients with known hypersensitivity to phenothiazines or aliphatic derivatives. It must not be administered to individuals in comatose states or those experiencing severe central nervous system depression from alcohol, barbiturates, or opiates. Patients with bone marrow depression, severe cardiovascular disease, or narrow-angle glaucoma should avoid this medication.

Triflupromazine: Pregnancy & Fertility

Safety data regarding Triflupromazine during pregnancy indicate potential risks of extrapyramidal signs or withdrawal symptoms in newborns when used late in the third trimester. Use during pregnancy or breastfeeding requires a strict risk-to-benefit evaluation by a physician. Studies regarding the direct impact of Triflupromazine on human fertility demonstrate potential alterations in prolactin levels, which may temporarily affect ovulation.

Tell Your Doctor Before Taking Triflupromazine

Inform your physician if you have a history of seizure disorders, Parkinson’s disease, or hepatic impairment. Disclose any existing cardiovascular conditions, such as arrhythmias, hypotension, or heart failure. Report all current prescription central nervous system medications, anticholinergic drugs, and over-the-counter supplements.

Triflupromazine: Dosage & Administration

Triflupromazine was historically formulated as oral tablets and injectable solutions for intramuscular or intravenous administration. Administering phenothiazine injections requires careful clinical supervision.

• Parenteral Injection: Administered via deep intramuscular injection or slow intravenous line by medical staff.
• Oral Formulations: Historically taken with water according to precise physician dosing schedules.
• Clinical Setting: Typically administered in hospital or emergency environments for acute symptom control.

Standard Triflupromazine Dosing

For acute nausea and vomiting in adults, historical parenteral dosing ranged from 5 mg to 15 mg administered intramuscularly, titrated based on patient weight and clinical response. In psychiatric management, higher parenteral or oral doses were adjusted under strict clinical supervision. Pediatric dosages were calculated strictly according to body weight.

How Triflupromazine Is Administered

Parenteral Triflupromazine should be injected slowly into deep muscular tissue to prevent local tissue irritation. Patients receiving intravenous or intramuscular doses should remain lying down for a short period to prevent orthostatic hypotension.

Triflupromazine: Clinical Efficacy & Research

Established clinical consensus confirms that Triflupromazine is a highly effective D2 receptor antagonist for controlling acute emesis. Clinical trials demonstrate that its central chemoreceptor trigger zone blockade produces rapid antiemetic action, significantly shortening episodes of severe vomiting. While newer antiemetics with fewer neurological side effects have largely superseded phenothiazines in routine gastroenterology care, historical research validates its strong efficacy in both gastrointestinal and psychiatric symptom management.

Triflupromazine: Side Effects & Safety Profile

Triflupromazine can induce central nervous system and autonomic side effects due to its multi-receptor binding activity.

Common Triflupromazine Side Effects

• Drowsiness, sedation, and mild lethargy
• Dry mouth, blurred vision, and urinary hesitation from anticholinergic action
• Orthostatic hypotension (dizziness upon standing up)
• Mild nasal congestion or constipation

Serious Triflupromazine Adverse Events

• Extrapyramidal symptoms, including acute dystonia, akathisia, and pseudoparkinsonism
• Tardive dyskinesia (involuntary repetitive facial and body movements) after long-term use
• Neuroleptic Malignant Syndrome (NMS), characterized by high fever, muscle rigidity, and autonomic instability
• Severe blood dyscrasias, including agranulocytosis or leukopenia

Managing Triflupromazine Side Effects

If dizziness or orthostatic lightheadedness occurs, have the patient lie down immediately and elevate the legs. If signs of muscle rigidity, high fever, or severe involuntary muscle spasms develop, discontinue Triflupromazine immediately and initiate emergency medical support.

Triflupromazine: Interactions & What to Avoid

Combining Triflupromazine with other central depressants or QT-prolonging agents increases toxicity risks significantly.

Triflupromazine: Interactions

• Central nervous system depressants (barbiturates, opioids, sedatives): Enhance CNS depression and respiratory sedation.
• Anticholinergic medications: Increase risks of severe dry mouth, paralytic ileus, hyperthermia, and urinary retention.
• Antihypertensive drugs: May cause additive hypotensive effects, leading to severe blood pressure drops.

Triflupromazine: Food & Alcohol

Avoid consuming alcohol while taking Triflupromazine, as alcohol severely potentiates central nervous system depression and sedation. Food does not significantly alter oral absorption, but taking oral forms with milk or meals reduces initial gastric upset.

Triflupromazine: Missed Dose, Overdose & Storage

Strict adherence to clinical dosing schedules prevents therapeutic gaps and accidental overexposure.

Missed Dose of Triflupromazine

If a scheduled dose of Triflupromazine is missed in a clinical setting, administer it as soon as remembered unless it is near the next scheduled time. Do not double the dose to make up for a missed application.

Triflupromazine: Overdose & Emergency

Triflupromazine overdose manifests as extreme somnolence, coma, severe extrapyramidal reactions, hypotension, and cardiac arrhythmias. Immediate emergency medical intervention, supportive airway management, and cardiovascular monitoring in an intensive care setting are required.

How To Store Triflupromazine

Store Triflupromazine injection vials and tablets at controlled room temperature between 15°C and 30°C (59°F and 86°F). Protect the medication from light and freezing conditions, and keep all containers out of reach of children.

Triflupromazine: Patient Management & Monitoring

Systematic patient monitoring ensures safe administration and early detection of adverse reactions.

Tests Before Starting Triflupromazine

• Baseline complete blood count (CBC) to assess liver function and white blood cell levels.
• Cardiovascular evaluation, including baseline blood pressure and electrocardiogram (ECG) screening.

Monitoring During Triflupromazine Treatment

• Continuous blood pressure monitoring following parenteral administration to detect orthostatic changes.
• Regular observation for early neurological signs of extrapyramidal side effects or involuntary movements.

Triflupromazine: Do’s and Don’ts

• Do keep patients recumbent for thirty minutes after receiving intravenous or intramuscular injections.
• Do monitor hydration levels and bowel habits during antiemetic therapy.
• Don’t operate machinery or drive while under the influence of Triflupromazine.
• Don’t abruptly stop long-term therapy without clinical supervision.

Frequently Asked Questions

References

• United States Food and Drug Administration. Vesprin (Triflupromazine Hydrochloride) Historical Prescribing Information.
• DrugBank Online Database. Triflupromazine Compound Summary (Accession Number DB00508).
• World Health Organization Collaborating Centre for Drug Statistics Methodology. ATC/DDD Index: N05AA05 (Triflupromazine).
• Official FDA Label (No active US FDA label URL available; drug status classified as Withdrawn).

Legal Disclaimer

The information provided is for educational and informational purposes only and does not constitute medical advice. Always consult a qualified healthcare provider at any hospital or any local clinic before starting or stopping any medication.